of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012; 35: 252–58.  6 Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once  weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301–10.  7 MacConell L, Maggs D, Li Y , Griﬃ   n P, Wysham C. Eﬃ   cacy and  safety of exenatide once weekly over 5 years. Diabetologia 2013; 56: S393.  8 Diamant M, Van Gaal L, Stranks S, et al. Safety and eﬃ   cacy of  once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 2012; 35: 683–89.  9 World Medical Association. World Medical Association Declaration  of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000; 284: 3043–45.